The ability of lonidamine to modulate the lethal activity of epirubicin, an adriamycin analog, was evaluated in a human multidrug resistant breast cancer cell line (MCF7 ADM). Our data show that lonidamine induces a strong inhibition of DNA synthesis and impairment of mitochondrial activity in epirubicin-damaged cells, thus potentiating the antineoplastic activity of the adriamycin derivative. This study provides evidence that drug resistance could be modulated by lonidamine and indicates the potential usefulness of lonidamine in combination with epirubicin for the treatment of breast cancer patients.
|Number of pages||4|
|Journal||International Journal of Oncology|
|Publication status||Published - 1994|
- breast cancer
ASJC Scopus subject areas
- Cancer Research